August 2, 2025 – At the recently concluded 7th CMC CHINA Expo & Future Medicine Industry Summit 2025, Dr. Zhang Yandong, Founder and CEO of Shenzhen KeYe Life Technology Co., Ltd., was honored with the "New Drug Pioneering Scientist Award" in recognition of her outstanding contributions to innovative drug R&D. This accolade not only affirms Dr. Zhang's personal scientific research capabilities but also serves as a high recognition of KeYe Life Technology's innovative strength in the biopharmaceutical field.

CMC CHINA is one of the most influential events in China's pharmaceutical industry. This year's expo, themed "Intelligence Leads the Future of Medicine, Innovation Drives Development," gathered top global pharmaceutical companies, research institutions, and industry leaders. Among its honors, the "Future Medicine New Species Top 100 Award" recognizes companies and individuals demonstrating breaking innovation in pharmaceutical technology, business models, or therapeutics, while the "New Drug Pioneering Scientist Award" is specifically bestowed upon scientists achieving breakthrough progress in original drug development.

As the founder of KeYe Life Technology, Dr. Zhang Yandong has long been dedicated to the field of small molecule drugs. Under her leadership, the team successfully developed a small molecule inhibitor targeting RNA helicase with broad-spectrum anti-cancer activity, filling a domestic technological gap and providing novel solutions for the treatment of major diseases. This award highlights eYe Life Technology's leading position in cutting-edge pharmaceutical research.